<DOC>
	<DOCNO>NCT01405989</DOCNO>
	<brief_summary>The primary objective study determine effect ketoconazole blood concentration darexaban metabolite ( drug degradation product ) . The secondary objective study evaluate safety tolerability single dose darexaban alone administer together ketoconazole .</brief_summary>
	<brief_title>To Evaluate Multiple Doses Ketoconazole Change Blood Concentration YM150 ( Darexaban )</brief_title>
	<detailed_description>This open-label , 2-period crossover study young healthy male subject evaluate effect multiple daily dos ketoconazole pharmacokinetics ( PK ) darexaban metabolite single dose darexaban . In addition , safety tolerability darexaban administer alone combination ketoconazole , evaluate . Eligible subject admit clinical unit morning Day -1 . The subject randomize receive either first darexaban plus ketaconazole darexaban alone , first darexaban alone follow darexaban plus ketoconazole .</detailed_description>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Darexaban</mesh_term>
	<criteria>Body mass index ( BMI ) 18.530.0 kg/m2 Male subject must nonfertile , i.e . surgically sterilize must practice adequate contraceptive method prevent pregnancy Known suspect hypersensitivity darexaban ketoconazole component formulation use Any liver function test ( i.e . ALT , AST bilirubin ) upper limit normal repeated measure Any clinically significant history disease disorder gastrointestinal , cardiovascular , respiratory , renal , hepatic , neurological , dermatological , psychiatric metabolic judge medical investigator Any clinically significant abnormality follow investigator 's review prestudy physical examination , ECG clinical laboratory test Use prescribed OTC ( overthecounter ) drug ( include vitamin , natural herbal remedy , e.g . St. John 's wort ) 2 week prior admission Clinical Unit , except occasional use paracetamol ( 3 g/day ) Regular use inducer liver metabolism ( e.g . barbiturate , rifampicin ) 3 month prior admission Clinical Unit Donation blood blood product within 3 month prior admission Clinical Unit Any use drug abuse , smoke 10 cigarette ( equivalent ) 21 unit ( 210 g ) alcohol per week within 3 month prior study Participation clinical study within 3 month participation 3 clinical study within 12 month , prior expect date enrolment study , provide clinical study entail biological compound long terminal half life</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>darexaban</keyword>
	<keyword>ketoconazole</keyword>
	<keyword>Phase 1</keyword>
</DOC>